Researchers Predict Which Antibodies Provide Best Protection Against SARS-CoV-2 and Which COVID-19 Vaccines Might Help
By HospiMedica International staff writers Posted on 25 Sep 2020 |
Illustration
Researchers from Leiden University Medical Center (LUMC Leiden, the Netherlands) have published a perspective article about coronavirus and its characteristic ‘spike protein.’ They predict which antibodies would provide the best protection against the virus and which vaccines might help.
In their article, the researchers from the LUMC’s Immunology department have described how the human immune system responds to coronavirus. Coronavirus (SARS-CoV-2) is a new microorganism. This means, say the researchers, that we need a well-functioning immune system that can quickly and efficiently produce antibodies to the virus, a process that the researchers are further investigating in two joint LUMC studies. For their publication, the LUMC researchers used bioinformatics tools to conduct an in-depth analysis of published data. They have concluded that the binding of the virus’s spike protein to the human mucous membranes is unusually high. The current binding domain of this viral spike protein appears to have remained unchanged since the initial outbreak in China in November 2019. According to the study co-author Jacques van Dongen, this binds almost ‘perfectly’ – with no fewer than 18 contact points – to the human ACE2 protein, something that is very uncommon in nature.
This information about the viral protein and its role tells the immunologists that our immune system has to produce what are known as neutralizing antibodies, which preferably immediately block the contact between the spike protein and the human ACE2 molecule. The contact domain is unusually large, however, and the spike protein has a high binding-affinity. The researchers have, therefore, concluded that a person who has been infected or immunized should preferably produce several (different) antibodies that target the different sections of the viral spike protein’s binding domain. In their article, the researchers have also predicted which types of antibody and vaccine would be most effective.
Related Links:
Leiden University Medical Center (LUMC)
In their article, the researchers from the LUMC’s Immunology department have described how the human immune system responds to coronavirus. Coronavirus (SARS-CoV-2) is a new microorganism. This means, say the researchers, that we need a well-functioning immune system that can quickly and efficiently produce antibodies to the virus, a process that the researchers are further investigating in two joint LUMC studies. For their publication, the LUMC researchers used bioinformatics tools to conduct an in-depth analysis of published data. They have concluded that the binding of the virus’s spike protein to the human mucous membranes is unusually high. The current binding domain of this viral spike protein appears to have remained unchanged since the initial outbreak in China in November 2019. According to the study co-author Jacques van Dongen, this binds almost ‘perfectly’ – with no fewer than 18 contact points – to the human ACE2 protein, something that is very uncommon in nature.
This information about the viral protein and its role tells the immunologists that our immune system has to produce what are known as neutralizing antibodies, which preferably immediately block the contact between the spike protein and the human ACE2 molecule. The contact domain is unusually large, however, and the spike protein has a high binding-affinity. The researchers have, therefore, concluded that a person who has been infected or immunized should preferably produce several (different) antibodies that target the different sections of the viral spike protein’s binding domain. In their article, the researchers have also predicted which types of antibody and vaccine would be most effective.
Related Links:
Leiden University Medical Center (LUMC)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans